A Phase III, Multi-center, Randomized, Double-blinded, Parallel Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues
Latest Information Update: 02 Jan 2024
At a glance
- Drugs Besifovir (Primary) ; Levocarnitine; Tenofovir
- Indications Hepatitis B
- Focus Registrational; Therapeutic Use
- Sponsors Ildong Pharmaceutical
- 14 Nov 2023 Results assessing incidence of HCC under BSV therapy using clinical trial and retrospective real-world BSV data and comparison with that observed during entecavir (ETV) or tenofovir disoproxil fumarate (TDF) therapy presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
- 09 Aug 2022 Status changed from recruiting to completed.
- 27 Nov 2018 Planned End Date changed from 1 Dec 2017 to 1 Feb 2020.